Gland Pharma posted a 12 per cent increase in consolidated net profit at ₹184 crore in the second quarter ended September 30, 2025, compared to ₹163 crore in the corresponding quarter in the previous financial year. The total revenue of the Hyderabad-based company increased 6 per cent to ₹1,486 crore against ₹1,405 crore in the same period last year.

“We expect stronger momentum in the second half, driven by new launches and Cenexi’s recovery. Our investments in global CDMO expansion, capacity enhancement in high-end modalities and complex injectables pipeline continue to strengthen our foundation and support sustainable growth and long-term value for all stakeholders,’’ said Srinivas Sadu, Executive Chairman, Gland Pharma, in a release on Monday.

Shyamakant Giri, Chief Executive Officer

See Full Page